SCHEMBL4665690

SCHEMBL4665690

Cc1ccc(S(=O)(=O)Nc2ccc(Nc3cc(-c4cccnc4)ncn3)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.54
ALDH1A1 P00352 5/20 0.52
NAMPT P43490 1/20 0.51
LMNA P02545 2/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GAA P10253 1/20 0.49
CKS1B P61024 1/20 0.48
SKP2 Q13309 1/20 0.48
CYP1A2 P05177 3/20 0.48
CYP3A4 P08684 3/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C19 P33261 2/20 0.48
BACE1 P56817 2/20 0.48
CLK4 Q9HAZ1 2/20 0.48
KDM4E B2RXH2 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665854 0.89 BACE1 (0.60) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL12907691 0.89 CYP3A4 (0.58) POLBALDH1A1LMNAMEN1KMT2A
SCHEMBL4664324 0.88 ABL1 (0.55) ALDH1A1NAMPTLMNAMEN1KMT2A
SCHEMBL4664257 0.84 CCNT1 (0.64) MEN1KMT2AGAACYP1A2CYP3A4
SCHEMBL4098855 0.83 MAPT (0.53) ALDH1A1LMNAMEN1KMT2AGAA
SCHEMBL4109389 0.82 EGFR (0.54) SMN1; SMN2LMNAMEN1KMT2AGAA
SCHEMBL4667533 0.82 PIM1 (0.59) ALDH1A1LMNAMEN1KMT2AGAA
SCHEMBL4664298 0.82 MEN1 (0.51) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL4665763 0.82 CCNT1 (0.59) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL6027168 0.82 ALDH1A1 (0.61) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US claimed
EP-1709007-A1 N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS Altana Pharma AG (DE) 2006-10-11 EP claimed
WO-2005070900-A1 N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS ALTANA PHARMA AG (DE) 2005-08-04 WO claimed
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed
EP-1709007-A1 N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS Altana Pharma AG (DE) 2006-10-11 EP disclosed
WO-2005070900-A1 N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS ALTANA PHARMA AG (DE) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 POLB 2689/4885SMN1; SMN2 3846/4885ALDH1A1 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.